Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Bioventus Inc (BVS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/10/2025: BVS (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $14.67
1 Year Target Price $14.67
| 2 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 79.35% | Avg. Invested days 31 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 11/10/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 498.97M USD | Price to earnings Ratio 46.56 | 1Y Target Price 14.67 |
Price to earnings Ratio 46.56 | 1Y Target Price 14.67 | ||
Volume (30-day avg) 3 | Beta 0.8 | 52 Weeks Range 5.81 - 12.61 | Updated Date 11/10/2025 |
52 Weeks Range 5.81 - 12.61 | Updated Date 11/10/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.16 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-04 | When - | Estimate 0.1085 | Actual 0.15 |
Profitability
Profit Margin 1.8% | Operating Margin (TTM) 8.13% |
Management Effectiveness
Return on Assets (TTM) 4.14% | Return on Equity (TTM) 6.38% |
Valuation
Trailing PE 46.56 | Forward PE 7.63 | Enterprise Value 757175353 | Price to Sales(TTM) 0.89 |
Enterprise Value 757175353 | Price to Sales(TTM) 0.89 | ||
Enterprise Value to Revenue 1.34 | Enterprise Value to EBITDA 8.71 | Shares Outstanding 66976477 | Shares Floating 33804367 |
Shares Outstanding 66976477 | Shares Floating 33804367 | ||
Percent Insiders 11.76 | Percent Institutions 73.53 |
Upturn AI SWOT
Bioventus Inc
Company Overview
History and Background
Bioventus Inc. was founded in 2012 as a spin-off from Smith & Nephew's biologics division. It focuses on developing and marketing orthobiologic solutions. Since its inception, it has grown through acquisitions and organic product development.
Core Business Areas
- Active Healing Therapies: This segment focuses on products that promote bone and tissue healing, including bone growth stimulators, ultrasound healing systems, and hyaluronic acid injections.
- Surgical Solutions: This segment is centered on products used in surgical procedures to enhance bone fusion, tissue repair and regeneration, including bone graft substitutes and resorbable fixation devices.
- Pain Relief: This segment focuses on non-surgical pain management products, primarily focusing on hyaluronic acid injections used to treat osteoarthritis pain.
Leadership and Structure
Kenneth Reali serves as the Chief Executive Officer. The company has a traditional corporate structure with a board of directors and various executive leadership roles overseeing different functional areas such as finance, marketing, and operations.
Top Products and Market Share
Key Offerings
- EXOGEN Ultrasound Bone Healing System: EXOGEN is a non-invasive ultrasound device used to accelerate fracture healing. Bioventus holds a significant market share in the ultrasound bone healing system market. Key competitors include Orthofix and DJO Global. Specific market share data and revenue are not publicly and readily disclosable as it is considered company proprietary information. This product falls under the Active Healing Therapies segment.
- DUROLANE: DUROLANE is a single-injection hyaluronic acid (HA) product used for osteoarthritis pain relief. It competes with other HA injections like Synvisc (Sanofi) and Orthovisc (DePuy Synthes). Bioventus holds a competitive share in the HA injection market. Specific market share data and revenue are not publicly and readily disclosable as it is considered company proprietary information. This product falls under the Pain Relief segment.
- OSTEOAMP: OSTEOAMP is a family of bone graft products used in spinal fusion and other orthopedic surgeries. These are alternatives to traditional bone grafts and other bone substitutes. Competitors include Medtronic and Stryker. Specific market share data and revenue are not publicly and readily disclosable as it is considered company proprietary information. This product falls under the Surgical Solutions segment.
Market Dynamics
Industry Overview
The orthobiologics market is growing due to an aging population, increasing prevalence of orthopedic conditions, and advancements in regenerative medicine. The market is competitive with both large and small players offering a range of products.
Positioning
Bioventus is positioned as a key player in the orthobiologics market, focusing on active healing, surgical solutions, and pain management. Its competitive advantages include a diverse product portfolio, strong brand recognition, and established distribution channels.
Total Addressable Market (TAM)
The global orthobiologics market is projected to reach billions of dollars. Estimates vary but it could be $10 Billion USD by 2028. Bioventus is well-positioned to capture a significant portion of this market with its portfolio.
Upturn SWOT Analysis
Strengths
- Diverse product portfolio
- Established distribution network
- Strong brand recognition
- Focus on innovation in orthobiologics
Weaknesses
- Reliance on key products
- Exposure to reimbursement pressures
- Competition from larger players
- High research and development costs
Opportunities
- Expansion into new geographic markets
- Development of new orthobiologic products
- Acquisition of complementary technologies
- Partnerships with healthcare providers
Threats
- Increased competition
- Changes in reimbursement policies
- Regulatory hurdles
- Economic downturns
Competitors and Market Share
Key Competitors
- Zimmer Biomet (ZBH)
- Stryker Corporation (SYK)
- Medtronic (MDT)
- Smith & Nephew (SNN)
Competitive Landscape
Bioventus competes with larger orthopedic companies and specialized orthobiologics firms. Its advantages include focused orthobiologic portfolio and strong brand recognition in certain segments. Disadvantages include smaller scale and limited financial resources compared to larger competitors.
Major Acquisitions
Misonix
- Year: 2021
- Acquisition Price (USD millions): 518
- Strategic Rationale: Expanded Bioventus's surgical solutions portfolio with ultrasonic surgical devices.
Growth Trajectory and Initiatives
Historical Growth: Bioventus has grown through organic product development and acquisitions. Historical revenue growth rates can be derived from past financial reports.
Future Projections: Future growth projections depend on market conditions, product launches, and strategic initiatives. Analyst estimates can be found on financial websites.
Recent Initiatives: Recent initiatives may include new product launches, acquisitions, and partnerships.
Summary
Bioventus is a focused orthobiologics company with a diverse portfolio and strong brand in certain segments. Its active healing products and surgical solutions are key drivers. The company faces competition from larger players and reimbursement pressures. However, it has opportunities for growth through new product development, geographic expansion, and strategic acquisitions.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings
- Market research reports
- Analyst estimates
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market data and financial metrics are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bioventus Inc
Exchange NASDAQ | Headquaters Durham, NC, United States | ||
IPO Launch date 2021-02-11 | President, CEO & Director Mr. Robert E. Claypoole | ||
Sector Healthcare | Industry Medical Devices | Full time employees 930 | Website https://www.bioventus.com |
Full time employees 930 | Website https://www.bioventus.com | ||
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise of various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides nexus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company's restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system; and Talisman pulse generator and receiver for peripheral nerve stimulation. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.